SEARCH
Tynax ~ Patent Library

Technology for License:

Dengue Tetravalent Vaccine    

Novel recombinant envelop based tetravalent protein which elicits protective immune responses against four serotypes of dengue virus

Overview

The technology describes a novel recombinant envelop domain-III based tetravalent protein which elicits protective immune responses against each of the four serotypes of dengue virus, DEN-1, DEN-2, DEN-3 and DEN-4. Hence it is capable of inhibiting the infectivity of each dengue virus serotype which is responsible for different form of dengue fever. The technology further suggests a process for the preparation of this tetravalent protein which involves codon optimizing the sequence, followed by cloning, transforming and purifying the novel recombinant tetravalent protein. This technology has been tested on mice.

The Problem Solved by the Technology

Tetravalent formulations, obtained by mixing these monovalent vaccine viruses, corresponding to the four serotypes, are prone to elicit an un-balanced immune response, predominantly to one serotype, due to viral interference.

How the Technology Solves the Problem

A novel recombinant envelop domain-III based tetravalent protein which elicits protective immune responses against each of the four serotypes of dengue virus, DEN-1, DEN-2, DEN-3 and DEN-4. Hence it is capable of inhibiting the infectivity of each dengue virus serotype which is responsible for different form of dengue fever.

Primary Application of the Technology

Against dengue fever

Competitive Advantage

Effective against different types of dengue serotypes.

Notes on Development Status

Early stage

Comments on Deal Structure, Potential Terms and Restrictions

Available for licensing; Buyer-side commission fee